A003000 Stock Overview
Develops, produces, and sells pharmaceutical products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Bukwang Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,620.00 |
| 52 Week High | ₩9,000.00 |
| 52 Week Low | ₩4,070.00 |
| Beta | -0.16 |
| 1 Month Change | -0.54% |
| 3 Month Change | -10.29% |
| 1 Year Change | -24.26% |
| 3 Year Change | -64.19% |
| 5 Year Change | -63.83% |
| Change since IPO | 879.96% |
Recent News & Updates
Bukwang Pharmaceutical (KRX:003000) Has Debt But No Earnings; Should You Worry?
Nov 13
Is Bukwang Pharmaceutical (KRX:003000) Weighed On By Its Debt Load?
May 22Recent updates
Bukwang Pharmaceutical (KRX:003000) Has Debt But No Earnings; Should You Worry?
Nov 13Is Bukwang Pharmaceutical (KRX:003000) Weighed On By Its Debt Load?
May 22Investors In Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Should Consider This, First
Apr 03Did Bukwang Pharmaceutical's (KRX:003000) Share Price Deserve to Gain 71%?
Mar 08Is Bukwang Pharmaceutical (KRX:003000) A Risky Investment?
Feb 10How Much Of Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Do Insiders Own?
Jan 14Does It Make Sense To Buy Bukwang Pharmaceutical Co., Ltd. (KRX:003000) For Its Yield?
Dec 19Did You Miss Bukwang Pharmaceutical's (KRX:003000) 90% Share Price Gain?
Nov 23Shareholder Returns
| A003000 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -2.6% | -0.5% | -1.9% |
| 1Y | -24.3% | 0.8% | -9.5% |
Return vs Industry: A003000 underperformed the KR Pharmaceuticals industry which returned 0.8% over the past year.
Return vs Market: A003000 underperformed the KR Market which returned -9.5% over the past year.
Price Volatility
| A003000 volatility | |
|---|---|
| A003000 Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A003000 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A003000's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1960 | 556 | Jae-Young Lee | www.bukwang.co.kr |
Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, liver cirrhosis, and iron-deficiency anemia; over-the-counter drugs, such as fever and pain relief medication, gastrointestinal medication, cold medication, laxatives for constipation, collagen supplements, multivitamin supplements, mouthwash, topical gels, oral health supplements, and omega-3 supplements; and personal products comprising toothpastes, toothbrushes, and other oral care products; nutraceuticals; health functional foods; and quasi drugs.
Bukwang Pharmaceutical Co., Ltd. Fundamentals Summary
| A003000 fundamental statistics | |
|---|---|
| Market cap | ₩314.55b |
| Earnings (TTM) | -₩15.29b |
| Revenue (TTM) | ₩138.93b |
2.3x
P/S Ratio-20.7x
P/E RatioIs A003000 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A003000 income statement (TTM) | |
|---|---|
| Revenue | ₩138.93b |
| Cost of Revenue | ₩79.65b |
| Gross Profit | ₩59.28b |
| Other Expenses | ₩74.56b |
| Earnings | -₩15.29b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -223.29 |
| Gross Margin | 42.67% |
| Net Profit Margin | -11.00% |
| Debt/Equity Ratio | 34.4% |
How did A003000 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 21:26 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bukwang Pharmaceutical Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Kyun Lim | IBK Securities Co. Ltd. |
| JongHoon Lee | Mirae Asset Securities Co., Ltd. (Pre-Merger) |
| Seung Kim | Samsung Securities Co. Ltd. |